Literature DB >> 9250795

Evaluation of Taxol cytotoxicity on B-CLL cells in vitro.

F Di Raimondo1, G A Palumbo, M A Romeo, F Galvagno, F Stagno, F Morabito, R Giustolisi.   

Abstract

Taxol is a new antimicrotubule agent that, besides a well known efficacy against solid tumors, has shown activity in non-Hodgkin's lymphomas too. We therefore investigated its in vitro cytotoxic activity against cells from patients affected by chronic lymphocytic leukemia (CLL). Peripheral blood lymphocytes from 46 CLL patients were incubated for four days with Taxol at doses ranging from 0.01 to 10 mM and the cytotoxicity was evaluated by a colorimetric method (XTT). In most samples Taxol was inactive and the IC50 was > 10 mM in 40 out of 46 patients. It is worthwhile noting that four of the six in vitro responsive patients had unfavourable clinical features. In three unresponsive patients we also observed that Taxol was not able to induce apoptosis in vitro. In conclusion, based on in vitro data, it seems that Taxol is not an active drug in standard CLL but we cannot exclude some efficacy in other more rapidly proliferating lymphoproliferative disorders.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9250795     DOI: 10.3109/10428199709109165

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  3 in total

1.  Phase I trial of fludarabine and paclitaxel in non-Hodgkin's lymphoma.

Authors:  Muhammad R Abbasi; Joseph A Sparano; Catherine Sarta; Peter H Wiernik
Journal:  Med Oncol       Date:  2003       Impact factor: 3.064

2.  Characterization of the TCL-1 transgenic mouse as a preclinical drug development tool for human chronic lymphocytic leukemia.

Authors:  Amy J Johnson; David M Lucas; Natarajan Muthusamy; Lisa L Smith; Ryan B Edwards; Michael D De Lay; Carlo M Croce; Michael R Grever; John C Byrd
Journal:  Blood       Date:  2006-05-02       Impact factor: 22.113

Review 3.  Granisetron in the control of nausea and vomiting associated with bone marrow transplantation: a review of its efficacy and tolerability.

Authors:  H G Prentice
Journal:  Support Care Cancer       Date:  2003-07-05       Impact factor: 3.603

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.